Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Use of rupatadine for preventing or treating pulmonary fibrosis

A technology for pulmonary fibrosis and uses, which is applied in the field of new uses of known drugs, can solve problems such as lack of treatment methods for pulmonary fibrosis, and achieve the effects of significant curative effect, less toxic and side effects, and safe use.

Active Publication Date: 2012-12-05
BEIJING WEIFENG YIMIN TECH +2
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0010] In summary, there is currently no effective treatment for pulmonary fibrosis. Therefore, there is an urgent need to develop new drugs with good curative effect in this field to alleviate or treat the symptoms of pulmonary fibrosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of rupatadine for preventing or treating pulmonary fibrosis
  • Use of rupatadine for preventing or treating pulmonary fibrosis
  • Use of rupatadine for preventing or treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] Example 1 Preparation of an animal model of pulmonary fibrosis

[0039] 1. Main reagents and experimental animals

[0040] The bleomycin used in the experiment was purchased from Nippon Kayaku, lot number X81040.

[0041] The SPF grade C57BL / 6 mice (male, 6-8 weeks old, 16-18 g) used in the experiment were purchased from the Institute of Zoology, Chinese Academy of Medical Sciences.

[0042] 2. Preparation method

[0043] The model of pulmonary fibrosis induced by bleomycin is the most recognized model of pulmonary fibrosis in the field of scientific research today. Bleomycin is an effective chemotherapeutic agent for skin cancer, but its medicinal value is limited by its dose-dependent pulmonary toxicity, which often manifests as pulmonary fibrosis. After administration of bleomycin, the alveolar endothelium was first damaged, and then bleomycin penetrated the injured alveolar endothelium to cause damage to the alveolar epithelial cells. Bleomycin causes lung damag...

Embodiment 2

[0046] Example 2 The method for treating pulmonary fibrosis with rupatadine

[0047] 1. Main reagents and experimental animals

[0048] Rupatadine, produced by Zhejiang Cifu Pharmaceutical Co., Ltd., is the raw material drug of rupatadine fumarate, and the content of rupatadine is >99%.

[0049] Pirfenidone, a drug that has been approved globally for the treatment of pulmonary fibrosis, has a good effect. The manufacturer of pirfenidone is Changzhou Wujin Qianhuang Sanyou Chemical Co., Ltd., which is the raw material drug, and the content of pirfenidone is >99%.

[0050] 2. Method

[0051] The animal model prepared in Example 1 was administered in groups after 7 days of modeling, and the grouping and administration were as shown in Table 1:

[0052] Table 1. Animal models of pulmonary fibrosis administered in groups 7 days after modeling

[0053]

[0054] Among them, A: Sham operation group (Sham); B: Model group (Model); C: Rupatadine 0.75mg / kg group (Rupa 0.75)...

Embodiment 3

[0055] Embodiment 3 measures mouse death rate

[0056] Calculated from the day of modeling as the 0th day, the death of experimental animals in each group was counted and calculated every day. The survival rate of animals in a certain group without death was calculated as 100%, and the survival rate of all animals in a certain group was calculated as 0%. The result See figure 1 . From figure 1 It can be seen that compared with the operation group, the mice were significantly dead after administration of bleomycin. Compared with the model group, the rupatadine 0.75 mg / kg and rupatadine 6 mg / kg groups can significantly reduce the death of mice caused by bleomycin.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses novel use of rupatadine for preventing or treating pulmonary fibrosis. The rupatadine is remarkable in curative effect for treating the pulmonary fibrosis, little toxic and side effect and safe in use.

Description

technical field [0001] The present invention belongs to the field of novel application of known medicines, and particularly relates to the application of rupatadine in the preparation of a pharmaceutical composition for preventing or treating pulmonary fibrosis. Background technique [0002] Tissue fibrosis is the common consequence of tissue damage caused by internal and external pathogens, and is also the basic pathological change of various infectious and non-infectious inflammatory diseases. Tissue fibrous hyperplasia is not only seen in various chronic lung diseases, cardiovascular diseases, chronic progressive kidney disease, liver cirrhosis, chronic pancreatitis, systemic lupus erythematosus and macular degeneration, but also can affect tumor growth and metastasis, and promote chronic rejection of organ transplantation The reaction happens. In fact, tissue fibrosis affects almost all organs and systems of the human body, is the main cause of disability and death in m...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4545A61P11/00
Inventor 胡卓伟吕晓希王晓星
Owner BEIJING WEIFENG YIMIN TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com